Russia Approves 2nd COVID-19 Vaccine EpiVacCorona,3rd One Almost Ready : President Vladimir Putin

Russia has given regulatory approval to a second Covid-19 vaccine, named ‘EpiVacCorona’, after early-stage studies.

Russia Approves 2nd COVID-19 Vaccine EpiVacCorona,3rd One Almost Ready : President Vladimir Putin
President Vladimir Putin

Russia has given regulatory approval to a second Covid-19 vaccine, named ‘EpiVacCorona’, after early-stage studies. The new coronavirus vaccine comes two months after an identical move for Russia’s first vaccine Sputnik V prompted widespread criticism from scientists both reception and abroad. Also Read - COVID-19 Vaccine Latest Update: Who are going to be the primary to be Cured of Coronavirus in India? Know Here

Russia became the primary country to offer regulatory approval to a Covid-19 vaccine in August when Sputnik V was officially registered before large-scale clinical test . Also Read - COVID-19 Vaccine Expected Soon in India, Experts Formulating Strategies For Its Distribution: Health Minister

During a televised meeting with officialdom on Wednesday, Russian President Putin announced that the country has registered the second Covid-19 vaccine. Putin said that a 3rd Russian vaccine against Covid-19, developed by the Chumakov Centre, would even be registered within the near future, Sputnik press agency reported.

We now got to increase production of the primary vaccine and therefore the second vaccine, Putin said. The president added that the priority was to provide the Russian market with the vaccines.The second Russian vaccine to receive regulatory approval was developed by the Vector State Research Centre of Virology and Biotechnology.

The two-shot vaccine, ‘EpiVacCorona’, was tested among 100 volunteers in early-stage, placebo-controlled human trials, which lasted quite two months and were completed fortnight ago. The volunteers were between 18 and 60 years old.

Vector’s vaccine EpiVacCorona relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant, consistent with details posted at ClinicalTrials.gov, a database of privately and publicly funded clinical studies conducted round the world.

Scientists have yet to publish the results of the study. In comments to the media, scientists developing the vaccine said that it produced enough antibodies to guard the one that had it from the virus which the immunity it creates could last for up to 6 months.

An advanced study involving tens of thousands of volunteers that's necessary to determine safety and effectiveness of the vaccine is scheduled to start out in November or December.Russian Deputy Prime Minister Tatyana Golikova said that she tested EpiVacCorona vaccine herself and experienced no side effects, said a media report.

Last Updated :